Selarsdi (ustekinumab-aekn) was approved by the FDA as an interchangeable biosimilar to Stelara (ustekinumab) for all approved indications, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.
The FDA has issued a safety alert on compounded topical finasteride products, citing adverse events and emphasizing the lack of regulatory approval or safety evaluation.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The FDA approved dupilumab as the first targeted therapy for chronic spontaneous urticaria in patients aged 12 years and older uncontrolled on antihistamines.
"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.
"Lip plumping will mostly appeal to women rather than men (who prefer thinner lips)," finds new research showing how lip size manipulations influence perceived facial attractiveness.
An invited commentary in JAAD reviewed current evidence indicating that exclusive breastfeeding for the first 3 to 4 months decreases cumulative incidence of atopic dermatitis in the first 2 years of life.